Annual CFO
-$135.49 M
+$39.34 M+22.50%
December 31, 2023
Summary
- As of February 7, 2025, ESPR annual cash flow from operations is -$135.49 million, with the most recent change of +$39.34 million (+22.50%) on December 31, 2023.
- During the last 3 years, ESPR annual CFO has fallen by -$50.31 million (-59.07%).
- ESPR annual CFO is now -1625.29% below its all-time high of -$7.85 million, reached on December 31, 1999.
Performance
ESPR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$35.33 M
-$28.12 M-390.28%
September 30, 2024
Summary
- As of February 7, 2025, ESPR quarterly cash flow from operations is -$35.33 million, with the most recent change of -$28.12 million (-390.28%) on September 30, 2024.
- Over the past year, ESPR quarterly CFO has dropped by -$28.12 million (-390.28%).
- ESPR quarterly CFO is now -125.34% below its all-time high of $139.39 million, reached on June 30, 2020.
Performance
ESPR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$25.76 M
-$16.00 M-163.97%
September 30, 2024
Summary
- As of February 7, 2025, ESPR TTM cash flow from operations is -$25.76 million, with the most recent change of -$16.00 million (-163.97%) on September 30, 2024.
- Over the past year, ESPR TTM CFO has dropped by -$16.00 million (-163.97%).
- ESPR TTM CFO is now -859.15% below its all-time high of -$2.69 million, reached on March 31, 2012.
Performance
ESPR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ESPR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | -390.3% | -164.0% |
| 3 y3 years | -59.1% | -390.3% | -164.0% |
| 5 y5 years | +8.8% | +39.1% | +63.4% |
ESPR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +48.6% | -165.6% | +38.8% | -164.0% | +90.2% |
| 5 y | 5-year | -92.6% | +48.6% | -125.3% | +60.3% | -164.0% | +91.2% |
| alltime | all time | -1625.3% | +48.6% | -125.3% | +60.3% | -859.1% | +91.2% |
Esperion Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$35.33 M(+390.3%) | -$25.76 M(+164.0%) |
| Jun 2024 | - | -$7.21 M(-113.4%) | -$9.76 M(-64.3%) |
| Mar 2024 | - | $53.83 M(-245.3%) | -$27.30 M(-79.8%) |
| Dec 2023 | -$135.49 M(-22.5%) | -$37.06 M(+91.8%) | -$135.49 M(-3.8%) |
| Sep 2023 | - | -$19.32 M(-21.9%) | -$140.90 M(-14.3%) |
| Jun 2023 | - | -$24.75 M(-54.5%) | -$164.41 M(-13.6%) |
| Mar 2023 | - | -$54.36 M(+28.0%) | -$190.19 M(+8.8%) |
| Dec 2022 | -$174.83 M(-33.7%) | -$42.47 M(-0.8%) | -$174.83 M(-8.0%) |
| Sep 2022 | - | -$42.83 M(-15.2%) | -$190.06 M(-12.2%) |
| Jun 2022 | - | -$50.53 M(+29.6%) | -$216.40 M(+1.2%) |
| Mar 2022 | - | -$38.99 M(-32.4%) | -$213.73 M(-19.0%) |
| Dec 2021 | -$263.81 M(+209.7%) | -$57.71 M(-16.6%) | -$263.81 M(-3.9%) |
| Sep 2021 | - | -$69.17 M(+44.5%) | -$274.65 M(-6.0%) |
| Jun 2021 | - | -$47.87 M(-46.3%) | -$292.15 M(+178.5%) |
| Mar 2021 | - | -$89.07 M(+29.9%) | -$104.90 M(+23.2%) |
| Dec 2020 | -$85.18 M(+21.1%) | -$68.55 M(-20.9%) | -$85.18 M(+27.9%) |
| Sep 2020 | - | -$86.67 M(-162.2%) | -$66.62 M(+75.4%) |
| Jun 2020 | - | $139.39 M(-301.0%) | -$37.98 M(-83.6%) |
| Mar 2020 | - | -$69.35 M(+38.7%) | -$231.38 M(+228.9%) |
| Dec 2019 | -$70.34 M(-52.7%) | -$49.99 M(-13.8%) | -$70.34 M(+43.4%) |
| Sep 2019 | - | -$58.03 M(+7.4%) | -$49.04 M(+71.8%) |
| Jun 2019 | - | -$54.01 M(-158.9%) | -$28.54 M(+107.9%) |
| Mar 2019 | - | $91.69 M(-419.6%) | -$13.73 M(-90.8%) |
| Dec 2018 | -$148.64 M(+13.2%) | -$28.69 M(-23.5%) | -$148.64 M(-4.0%) |
| Sep 2018 | - | -$37.53 M(-4.3%) | -$154.82 M(+1.1%) |
| Jun 2018 | - | -$39.20 M(-9.3%) | -$153.18 M(+9.3%) |
| Mar 2018 | - | -$43.22 M(+23.9%) | -$140.21 M(+6.8%) |
| Dec 2017 | -$131.30 M | -$34.87 M(-2.8%) | -$131.30 M(+16.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$35.88 M(+36.8%) | -$112.74 M(+23.7%) |
| Jun 2017 | - | -$26.23 M(-23.6%) | -$91.16 M(+26.2%) |
| Mar 2017 | - | -$34.32 M(+110.3%) | -$72.24 M(+51.4%) |
| Dec 2016 | -$47.73 M(+25.1%) | -$16.32 M(+14.1%) | -$47.73 M(+19.7%) |
| Sep 2016 | - | -$14.30 M(+95.8%) | -$39.86 M(+6.6%) |
| Jun 2016 | - | -$7.31 M(-25.5%) | -$37.39 M(-3.4%) |
| Mar 2016 | - | -$9.80 M(+16.0%) | -$38.70 M(+1.4%) |
| Dec 2015 | -$38.16 M(+19.2%) | -$8.45 M(-28.6%) | -$38.16 M(+0.6%) |
| Sep 2015 | - | -$11.83 M(+37.3%) | -$37.91 M(+9.2%) |
| Jun 2015 | - | -$8.61 M(-7.0%) | -$34.72 M(+7.9%) |
| Mar 2015 | - | -$9.26 M(+12.9%) | -$32.18 M(+0.5%) |
| Dec 2014 | -$32.02 M(+76.8%) | -$8.21 M(-4.9%) | -$32.02 M(+2.2%) |
| Sep 2014 | - | -$8.63 M(+42.0%) | -$31.34 M(+14.0%) |
| Jun 2014 | - | -$6.08 M(-33.2%) | -$27.49 M(+11.8%) |
| Mar 2014 | - | -$9.10 M(+20.9%) | -$24.59 M(+35.8%) |
| Dec 2013 | -$18.11 M(+67.6%) | -$7.53 M(+57.7%) | -$18.11 M(+39.9%) |
| Sep 2013 | - | -$4.78 M(+50.3%) | -$12.95 M(+16.9%) |
| Jun 2013 | - | -$3.18 M(+21.0%) | -$11.08 M(+3.1%) |
| Mar 2013 | - | -$2.63 M(+10.9%) | -$10.75 M(-0.5%) |
| Dec 2012 | -$10.81 M(+19.2%) | -$2.37 M(-18.5%) | -$10.81 M(+28.1%) |
| Sep 2012 | - | -$2.91 M(+2.1%) | -$8.44 M(+52.5%) |
| Jun 2012 | - | -$2.85 M(+6.0%) | -$5.53 M(+106.0%) |
| Mar 2012 | - | -$2.69 M | -$2.69 M |
| Dec 2011 | -$9.07 M(-65.9%) | - | - |
| Dec 2002 | -$26.56 M(+16.7%) | - | - |
| Dec 2001 | -$22.77 M(+26.8%) | - | - |
| Dec 2000 | -$17.95 M(+128.6%) | - | - |
| Dec 1999 | -$7.85 M | - | - |
FAQ
- What is Esperion Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Esperion Therapeutics?
- What is Esperion Therapeutics annual CFO year-on-year change?
- What is Esperion Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly CFO year-on-year change?
- What is Esperion Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Esperion Therapeutics?
- What is Esperion Therapeutics TTM CFO year-on-year change?
What is Esperion Therapeutics annual cash flow from operations?
The current annual CFO of ESPR is -$135.49 M
What is the all time high annual CFO for Esperion Therapeutics?
Esperion Therapeutics all-time high annual cash flow from operations is -$7.85 M
What is Esperion Therapeutics annual CFO year-on-year change?
Over the past year, ESPR annual cash flow from operations has changed by +$39.34 M (+22.50%)
What is Esperion Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ESPR is -$35.33 M
What is the all time high quarterly CFO for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly cash flow from operations is $139.39 M
What is Esperion Therapeutics quarterly CFO year-on-year change?
Over the past year, ESPR quarterly cash flow from operations has changed by -$28.12 M (-390.28%)
What is Esperion Therapeutics TTM cash flow from operations?
The current TTM CFO of ESPR is -$25.76 M
What is the all time high TTM CFO for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM cash flow from operations is -$2.69 M
What is Esperion Therapeutics TTM CFO year-on-year change?
Over the past year, ESPR TTM cash flow from operations has changed by -$16.00 M (-163.97%)